Financial Data and Key Metrics Changes - The company reported a non-cash profit of approximately $1.1 million from the divestment of a non-core manufacturing facility, which eliminated about $600,000 in annual operating expenses [22][23] - The company has renewed its $12 million line of credit and is focused on minimizing dilution while funding its business through selective capital raises [17] Business Line Data and Key Metrics Changes - IGC 81 is currently in a phase two trial, with over 50% enrollment completed, and the company is optimistic about finishing the trial in the first half of next year [4][9] - The CALMA trial has expanded to multiple sites in the U.S. and Canada, with significant acceleration in patient recruitment, increasing from four patients a month to 14 [35][36] Market Data and Key Metrics Changes - The company is targeting a significant unmet need in Alzheimer's treatment, with over 55 million diagnosed cases and 400 million individuals at risk due to Alzheimer's pathology [5][16] - The company is developing MINT-AD, an AI-based diagnostic platform aimed at early detection of Alzheimer's, which could help manage the risk for the 400 million individuals at risk [15][16] Company Strategy and Development Direction - The company is focused on advancing its pipeline of drugs, particularly IGC 81, as a disease-modifying therapy, while also developing MINT-AD for early detection of Alzheimer's [6][18] - The strategic divestment of the Vancouver manufacturing facility allows the company to redirect resources and management attention to accelerate the CALMA trial and other small molecule assets [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in completing the CALMA trial and achieving significant milestones in the upcoming year, which they believe will enhance shareholder value [18][42] - The company is insulated from potential regulatory changes affecting the hemp market, as its focus remains on pharmaceutical development and FDA approval [30][31] Other Important Information - The company is in the semi-final round for a $1 million prize for its AI program aimed at advancing Alzheimer's research, with a presentation scheduled for December 5 [17][37] - Management highlighted the importance of non-pharmacological interventions in delaying the onset of dementia, which aligns with their focus on early diagnosis and intervention [16] Q&A Session Summary Question: Will there be another interim data analysis before the trial completion? - Management confirmed that no further interim readouts are expected, focusing instead on completing the trial and the final readout [22] Question: What was the rationale behind the divestment of the Vancouver facility? - The divestment was strategic to eliminate operating expenses, redirect resources, and reduce management burdens while maintaining long-term supply rights for the white label business [22][23] Question: Are there plans for Canadian approval alongside U.S. approval for IGC 81? - Yes, the company plans to seek approval in both the U.S. and Canada, having received approval from Health Canada for the trial [25] Question: Will the new government funding bill impact the phase two trial? - Management stated that the bill targets the consumer hemp market and does not affect the regulatory pathway for prescription drugs like IGC 81 [30][31] Question: How is enrollment going for the CALMA trial? - Enrollment has significantly improved, with a notable increase in patient sign-ups due to effective advertising and geotargeting strategies [35][36] Question: What is the status of the $1 million award for the MINT program? - The company is in the semifinal round and will present its idea for accelerating Alzheimer's research using AI on December 5 [37]

Financial Data and Key Metrics Changes - The company reported a non-cash profit of approximately $1.1 million from the divestment of a non-core manufacturing facility, which eliminated about $600,000 in annual operating expenses [22][23] - The company has renewed its $12 million line of credit and is focused on minimizing dilution while funding its business through selective capital raises [17] Business Line Data and Key Metrics Changes - IGC 81 is currently in a phase two trial, with over 50% enrollment completed, and the company is optimistic about finishing the trial in the first half of next year [4][10] - The CALMA trial has expanded to multiple sites in the U.S. and Canada, with a focus on reducing agitation in Alzheimer's patients [10][11] Market Data and Key Metrics Changes - There are over 55 million people worldwide living with Alzheimer's, with an additional 400 million at risk due to prodromal conditions [5] - The company is developing an AI-based diagnostic platform, MINT-AD, aimed at early detection and predicting cognitive decline in individuals at risk for Alzheimer's [14][15] Company Strategy and Development Direction - The company is focused on advancing its pipeline of drugs, particularly IGC 81, as a disease-modifying therapy, while also developing MINT-AD for early detection of Alzheimer's [18] - The strategic divestment of the Vancouver manufacturing facility allows the company to redirect resources towards accelerating the CALMA trial and advancing other small molecule assets [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in completing the CALMA trial and achieving significant milestones in the upcoming year, which they believe will enhance shareholder value [18][31] - The company is not expecting any impact from recent legislation affecting the hemp industry on its pharmaceutical development and FDA approval processes [25][26] Other Important Information - The company is in the semi-final round for a $1 million prize aimed at advancing Alzheimer's research through AI, with a presentation scheduled for December 5 [30] - The company has received recognition for its work, including awards from the National Institute on Aging, highlighting its commitment to Alzheimer's research [30] Q&A Session Summary Question: Will there be another interim data analysis before the CALMA trial completion? - Management does not expect another readout and is focused on completing the trial and the final readout [21][22] Question: What was the rationale behind the divestment of the Vancouver manufacturing facility? - The divestment eliminated $600,000 in annual operating expenses, redirected resources to the CALMA trial, and secured long-term supply rights for the white label business [22][23] Question: Are there plans for Canadian approval in parallel with FDA approval for IGC 81? - Yes, the company plans to seek approval in both the U.S. and Canada as the trial is being conducted in both regions [24] Question: Will the recent government funding bill impact the phase two trial? - Management does not expect any impact as the trial is under rigorous regulatory oversight and focuses on pharmaceutical development, not the consumer hemp market [25][26] Question: How is enrollment going for the CALMA trial? - Enrollment has significantly increased, with a rise from four patients a month to 14, aided by online advertising and geotargeting [28][29]

Financial Data and Key Metrics Changes - The company reported a non-cash profit of approximately $1.1 million from the divestiture of a non-core manufacturing facility, which was sold for about $2.7 million [20][21] - The company has renewed its $12 million line of credit and is focused on minimizing dilution while maintaining a clean capital table [17] Business Line Data and Key Metrics Changes - IGC 81 is currently in a phase two trial, with over 50% enrollment completed, and the company is optimistic about finishing the trial in the first half of next year [4][9] - The CALMA trial, which focuses on agitation in Alzheimer's patients, has expanded to multiple sites in the U.S. and Canada, with a significant increase in patient recruitment [10][28] Market Data and Key Metrics Changes - The company is addressing a significant unmet need in the Alzheimer's market, with over 55 million diagnosed patients and 400 million at risk due to Alzheimer's pathology [5][16] - The company is developing an AI-based diagnostic platform, MINT-AD, aimed at early detection and prediction of cognitive decline in Alzheimer's patients [13][14] Company Strategy and Development Direction - The company is focused on advancing its multi-asset pipeline, particularly IGC 81, which is seen as a near-term opportunity to drive shareholder value [6][12] - The strategic divestiture of the Vancouver manufacturing facility allows the company to redirect resources and management attention towards accelerating the CALMA trial and advancing other small molecule assets [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in completing the CALMA trial and achieving significant milestones in the upcoming year, which they believe will enhance shareholder value [18][31] - The company is not expecting any impact from recent legislation affecting the hemp industry on its pharmaceutical development and FDA approval processes [24][25] Other Important Information - The company is in the semi-final round for a $1 million prize aimed at advancing Alzheimer's research through AI, with a presentation scheduled for December 5 [29][31] - The company has received recognition for its work, including awards from the National Institute on Aging, highlighting its commitment to Alzheimer's research [29] Q&A Session Summary Question: Will there be another interim data analysis before the trial completion? - Management indicated that they do not expect another readout and are focused on completing the trial and the final readout [20] Question: Why was the Vancouver manufacturing facility divested? - The divestiture was strategic to eliminate $600,000 in annual operating expenses and redirect resources to accelerate the CALMA trial [20][21] Question: Are there plans for Canadian approval alongside FDA approval? - Yes, the company plans to seek approval in both the U.S. and Canada as the trial is being conducted in both regions [23] Question: Will the recent government funding bill impact the phase two trial? - Management clarified that the bill targets the consumer hemp market and does not affect the regulatory pathway for prescription drugs like IGC 81 [24][25] Question: How is enrollment going for the CALMA trial? - Enrollment has significantly increased, with a rise from signing up four patients a month to 14, aided by online advertising and geotargeting [28]